Krilogy Financial LLC Takes $1.63 Million Position in Medpace Holdings, Inc. $MEDP

Krilogy Financial LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 3rd quarter, Holdings Channel reports. The fund purchased 3,164 shares of the company’s stock, valued at approximately $1,627,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quent Capital LLC acquired a new stake in Medpace in the 3rd quarter valued at approximately $25,000. Root Financial Partners LLC bought a new position in shares of Medpace in the third quarter worth $38,000. Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Medpace by 35.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after purchasing an additional 27 shares in the last quarter. Finally, Employees Retirement System of Texas bought a new stake in shares of Medpace during the second quarter valued at about $36,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective on the stock in a research note on Tuesday. Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. TD Cowen reaffirmed a “sell” rating on shares of Medpace in a report on Friday, October 24th. Finally, Truist Financial cut their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a report on Wednesday. Three research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus target price of $477.36.

Medpace Stock Down 5.0%

Shares of NASDAQ:MEDP opened at $423.93 on Thursday. The company’s fifty day moving average is $572.49 and its two-hundred day moving average is $538.75. The company has a market cap of $11.94 billion, a P/E ratio of 27.71, a price-to-earnings-growth ratio of 1.45 and a beta of 1.42. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Activity at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the sale, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction on Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This trade represents a 7.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 291,752 shares of company stock worth $175,731,579. Company insiders own 20.30% of the company’s stock.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Company beat Q4 revenue and EPS estimates and provided FY2026 EPS guidance (16.68–17.50), showing continued underlying growth momentum. Medpace (NASDAQ:MEDP) Reports Bullish Q4 CY2025
• Positive Sentiment: Medpace was selected as CRO by Zelluna for the ZIMA‑101 first‑in‑human trial — a business win that expands clinical services revenue opportunity. Zelluna selects Medpace as CRO
• Positive Sentiment: Robert W. Baird upgraded the stock to “outperform” with a $564 price target, signaling some analysts still see meaningful upside. Baird upgrade
• Neutral Sentiment: Earnings call transcript and presentation are available for investors digging into management’s remarks on backlog, book‑to‑bill and trial mix to judge forward revenue trajectory. Earnings call transcript
• Negative Sentiment: Several firms cut targets/ratings this morning — Barclays moved to “underweight” and trimmed its target to $500, Leerink lowered its target to $485 (market perform), and Truist cut to a $539 target with a “hold.” Those changes increase near‑term selling pressure. Analyst target changes Truist note
• Negative Sentiment: Market reaction focused on management’s comments about backlog normalization and trial‑mix shifts (metabolic trials), which tempered revenue growth expectations despite the beat — headlines flagged this as the “key negative.” Backlog normalization story
• Negative Sentiment: Coverage noted the stock dropped despite the beat, reflecting short‑term profit taking and concern that a strong quarter may already be priced in. Shares tumble despite beat

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.